<DOC>
	<DOCNO>NCT00580450</DOCNO>
	<brief_summary>The purpose trial determine safety efficacy 16 week treatment thymosin alpha 1 give 1.6 mg dose daily subcutaneous injection adult patient hematological undergone allogenic bone marrow transplantation CMV positive . The efficacy explore assess ability thymosin alpha1 prevent infection complication .</brief_summary>
	<brief_title>Thymosin Alfa 1 Recipients Allogeneic Hematopoietic Transplantation Hematological Malignancies</brief_title>
	<detailed_description>This open label , monocenter , explorative study . A total 9 patient include study three sequential cohort 3 patient . Patients enter study meeting inclusion exclusion criterion sign Informed Consent Form . The first three patient treat 16 week start 40 day transplantation ; three patient complete treatment period without serious treatment related adverse event recruitment second cohort patient open patient treat start 20 day transplantation . The procedure apply third cohort patient start treatment day transplantation .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Thymalfasin</mesh_term>
	<criteria>1 . Signed write informed consent . 2 . Age &gt; 18 &lt; 55 . 3 . Patients AML , ALL , haematological malignancy indication transplant without match donor undergo allogenic haploidentical hematopoietic transplantation ( see Appendix 2 ) follow category : Patients first complete remission ( CR ) high risk relapse unfavourable cytogenetics , : ( 9 ; 22 ) 11q23 translocation complex karyotype ( 8 ; 12 ) /ETV6AML ( 6 ; 9 ) /DEKCAN ( 11 ; 14 ) ( q15 , q11 ) Trisomy 13 FLT3/ITD Or adverse prognostic factor , : Secondary leukemia CR second line treatment High blast count Biphenotypic leukemia Patients 2nd 3rd CR chemoresistant relapse 4 . Recipient CMV positive measure pp65 antigenemia PCR 5 . Adequate cardiac function : Asymptomatic symptomatic leave ventricular ejection fraction rest &gt; 45 % must improve exercise , 6 . Adequate hepatic function : &lt; 2 x GOT GPT &lt; 2.0 mg total serum bilirubin unless liver involved disease , 7 . Adequate renal function : Serum creatinine within normal range serum creatinine outside normal range creatinine clearance &gt; 50 ml/min , 8 . Adequate Pulmonary function : Diffusion capacity &gt; 50 % predict ( correct hemoglobin ) 9 . Normal TSH evidence proper thyroid hormone replacement . 10 . For woman childbearing potential participating study , abstinence sexual intercourse use reliable form effective contraception treatment period . These may include , limited , birth control pill , IUDs , condom , diaphragm , implant , surgical sterilization , postmenopausal state . 11 . Negative pregnancy test prior first study medication dose . 1 . Evidence active hepatitis ( B and/or C ) cirrhosis 2 . HIV positive 3 . Presence active , uncontrolled bacterial , viral fungal infection 4 . Neurological psychiatric dysfunction would impair compliance medical regimen and/or transplantation toleration 5 . Concomitant prior history malignancy surgically cure situ carcinoma cervix . 6 . Pregnancy document urine pregnancy test lactation . 7 . Any indication patient would comply condition study protocol . 8 . Previous treatment thymosin alpha 1 . 9 . Simultaneous participation another investigational drug study participation clinical trial involve investigational drug within 3 month study entry .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2007</verification_date>
</DOC>